Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration,especially in orthodontic tooth movement.Abaloparatide(ABL),a synthetic analog of human PTHr P(1–34)and a clinical me...Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration,especially in orthodontic tooth movement.Abaloparatide(ABL),a synthetic analog of human PTHr P(1–34)and a clinical medication for treating osteoporosis,has recently demonstrated its potential in enhancing craniofacial bone formation.Herein,we show that intraoral submucosal injection of ABL,when combined with mechanical force,promotes in situ alveolar bone thickening.The newly formed bone is primarily located outside the original compact bone,implying its origin from the periosteum.RNA sequencing of the alveolar bone tissue revealed that the focal adhesion(FA)pathway potentially mediates this bioprocess.Local injection of ABL alone enhances cell proliferation,collagen synthesis,and phosphorylation of focal adhesion kinase(FAK)in the alveolar periosteum;when ABL is combined with mechanical force,the FAK expression is upregulated,in line with the accomplishment of the ossification.In vitro,ABL enhances proliferation,migration,and FAK phosphorylation in periosteal stem cells.Furthermore,the pro-osteogenic effects of ABL on alveolar bone are entirely blocked when FAK activity is inhibited by a specific inhibitor.In summary,abaloparatide combined with mechanical force promotes alveolar bone formation via FAK-mediated periosteal osteogenesis.Thus,we have introduced a promising therapeutic approach for drug-induced in situ alveolar bone augmentation,which may prevent or repair the detrimental periodontal dehiscence,holding significant potential in dentistry.展开更多
Neural EGFL-like 2(NELL2)is a secreted protein known for its regulatory functions in the nervous and reproductive systems,yet its role in bone biology remains unexplored.In this study,we observed that NELL2 was dimini...Neural EGFL-like 2(NELL2)is a secreted protein known for its regulatory functions in the nervous and reproductive systems,yet its role in bone biology remains unexplored.In this study,we observed that NELL2 was diminished in the bone of aged and ovariectomized(OVX)mice,as well as in the serum of osteopenia and osteoporosis patients.In vitro loss-of-function and gain-offunction studies revealed that NELL2 facilitated osteoblast differentiation and impeded adipocyte differentiation from stromal progenitor cells.In vivo studies further demonstrated that the deletion of NELL2 in preosteoblasts resulted in decreased cancellous bone mass in mice.Mechanistically,NELL2 interacted with the FNI-type domain located at the C-terminus of Fibronectin 1(Fn1).Moreover,we found that NELL2 activated the focal adhesion kinase(FAK)/AKT signaling pathway through Fn1/integrinβ1(ITGB1),leading to the promotion of osteogenesis and the inhibition of adipogenesis.Notably,administration of NELL2-AAV was found to ameliorate bone loss in OVX mice.These findings underscore the significant role of NELL2 in osteoblast differentiation and bone homeostasis,suggesting its potential as a therapeutic target for managing osteoporosis.展开更多
The published article titled“Procaine inhibits the proliferation and migration of colon cancer cells through inactivation of the ERK/MAPK/FAK pathways by regulation of RhoA”has been retracted from Oncology Research,...The published article titled“Procaine inhibits the proliferation and migration of colon cancer cells through inactivation of the ERK/MAPK/FAK pathways by regulation of RhoA”has been retracted from Oncology Research,Vol.26,No.2,2018,pp.209–217.展开更多
目的:研究粘着斑激酶(focal adhesion kinase,FAK)、磷酸化粘着斑激酶(phospho-FAK,Y397)、与张力蛋白同源的第10号染色体丢失的磷酸酶基因(phosphatase and tensinhomolog deleted on chromosome,PTEN)在胃腺癌及癌旁组织中的表达及其...目的:研究粘着斑激酶(focal adhesion kinase,FAK)、磷酸化粘着斑激酶(phospho-FAK,Y397)、与张力蛋白同源的第10号染色体丢失的磷酸酶基因(phosphatase and tensinhomolog deleted on chromosome,PTEN)在胃腺癌及癌旁组织中的表达及其临床意义。方法:采用免疫组织化学S-P法检测FAK、p-FAK(Y397)和PTEN在100例胃腺癌和30例癌旁组织中的表达。结果:胃腺癌与癌旁组织FAK阳性表达率分别为71%(71/100)、43%(13/30)(P<0.05);P-FAK(Y397)阳性表达率分别为62%(62/100)、20%(6/30)(P<0.05);PTEN阳性表达率分别为53%(53/100)、97%(29/30)(P<0.05);癌组织中FAK、p-FAK(Y397)、PTEN的表达与胃腺癌分化程度、浸润深度、淋巴结转移及TNM分期有关(P<0.05),与年龄、性别无关(P>0.05);PTEN与FAK、P-FAK(Y397)在胃腺癌中的表达呈负相关(r=-0.514,-0.572;P<0.05),FAK与p-FAK(Y397)呈正相关(r=0.539;P<0.05)。结论:胃腺癌中存在FAK和p-FAK(Y397)表达上调,PTEN表达下调,三者的表达水平可能与胃腺癌的发生、发展有关。展开更多
目的:研究青娥方对去卵巢大鼠骨组织FAK表达及骨代谢生化指标的影响。方法:96只3月龄雌性SD大鼠随机分为假手术组、单纯去卵巢组、骨疏康组、青娥方组。前两组灌服0.9%氯化钠溶液,后两组分别灌服骨疏康及青娥方。分别于用药4、8、12周...目的:研究青娥方对去卵巢大鼠骨组织FAK表达及骨代谢生化指标的影响。方法:96只3月龄雌性SD大鼠随机分为假手术组、单纯去卵巢组、骨疏康组、青娥方组。前两组灌服0.9%氯化钠溶液,后两组分别灌服骨疏康及青娥方。分别于用药4、8、12周检测大鼠腰椎FAK m RNA及蛋白含量、胫骨骨密度(BMD)、血清骨碱性磷酸酶(BALP)、酸性磷酸酶(TRAP-5b)、尿脱氧吡啶吩(DPD)、尿肌酐(Cr)等的变化。结果:用药4、8、12周,与假手术组比较,单纯去卵巢组骨FAK m RNA及蛋白表达明显升高(P<0.01),随着时间推移逐渐越低。BMD及血TRAP-5b持续下降,血BALP呈先升高后下降态势,尿DPD/Cr持续升高。青娥方干预4、8、12周,骨FAK m RNA及蛋白表达持续下降,明显低于单纯去卵巢组(P<0.05,P<0.01)。用药8、12周,与单纯去卵巢组比较,青娥方组血BALP、血TRAP-5b水平较之前明显改善(P<0.05,P<0.01);用药12周后,BMD及尿DPD/Cr明显高于单纯去卵巢组(P<0.01),与假手术组相比无明显差异。结论:青娥方能抑制骨组织FAK的表达,提高BMD及血BALP水平,降低血TRAP-5b及尿DPD/Cr含量,降低去卵巢大鼠的骨吸收速度。展开更多
目的观察化痰消瘀方对胃癌前病变大鼠PTEN、FAK及paxillin表达的影响,从分子生物学水平探讨其逆转胃癌前病变的作用机制。方法选择90只4~5周龄SD雄性大鼠,随机取15只作为空白组,其余大鼠均采用N-甲基-N’-硝基N-亚硝基胍综合饥饱失常、...目的观察化痰消瘀方对胃癌前病变大鼠PTEN、FAK及paxillin表达的影响,从分子生物学水平探讨其逆转胃癌前病变的作用机制。方法选择90只4~5周龄SD雄性大鼠,随机取15只作为空白组,其余大鼠均采用N-甲基-N’-硝基N-亚硝基胍综合饥饱失常、浓盐水灌胃的方法制备胃癌前病变大鼠模型。将造模成功大鼠随机分为模型组,中药高、中、低剂量组及维酶素组,每组13只。空白组正常饮食,余均造模成功后,模型组给予生理盐水灌胃,中药高、中、低剂量组分别给予3 m L/kg、2 m L/kg、1 m L/kg化痰消瘀方灌胃,维酶素组给予10 m L/kg维酶素灌胃,均灌胃8周。采用HE染色法观察大鼠胃黏膜病理改变情况,应用免疫组化法检测胃黏膜组织中PTEN、FAK及paxillin的表达情况。结果 HE染色显示空白组大鼠胃黏膜无癌前病变改变,模型组均出现不同程度的胃癌前病变改变,中药高、中剂量组和维酶素组胃黏膜癌前病变情况均较模型组明显改善（P均〈0.05）,且中药高剂量组改善程度高于其他各给药组（P均〈0.05）。免疫组化结果显示PTEN在空白组强阳性表达;模型组鲜有表达;中药高、中、低剂量组表达量逐渐降低,但高于模型组（P均〈0.05）;中药高剂量组PTEN表达量高于其他各给药组（P均〈0.05）。FAK、paxillin在空白组极少表达,模型组表达量较空白组显著增加（P均〈0.05）;中药高、中、低剂量组二者表达量均明显低于模型组（P均〈0.05）,其中高剂量组表达量明显低于其他各给药组（P均〈0.05）。结论中药化痰消瘀方可显著改善胃癌前病变大鼠胃黏膜组织病理学情况,其作用机制可能是激活抑癌基因PTEN,调节FAK的去磷酸化,通过FAK/Src信号通路下调paxillin来诱导细胞凋亡。展开更多
基金supported by the National Natural Science Foundation of China(NSFC)(82371003)the Elite Research Grant of the International Orthodontics Foundation 2022。
文摘Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration,especially in orthodontic tooth movement.Abaloparatide(ABL),a synthetic analog of human PTHr P(1–34)and a clinical medication for treating osteoporosis,has recently demonstrated its potential in enhancing craniofacial bone formation.Herein,we show that intraoral submucosal injection of ABL,when combined with mechanical force,promotes in situ alveolar bone thickening.The newly formed bone is primarily located outside the original compact bone,implying its origin from the periosteum.RNA sequencing of the alveolar bone tissue revealed that the focal adhesion(FA)pathway potentially mediates this bioprocess.Local injection of ABL alone enhances cell proliferation,collagen synthesis,and phosphorylation of focal adhesion kinase(FAK)in the alveolar periosteum;when ABL is combined with mechanical force,the FAK expression is upregulated,in line with the accomplishment of the ossification.In vitro,ABL enhances proliferation,migration,and FAK phosphorylation in periosteal stem cells.Furthermore,the pro-osteogenic effects of ABL on alveolar bone are entirely blocked when FAK activity is inhibited by a specific inhibitor.In summary,abaloparatide combined with mechanical force promotes alveolar bone formation via FAK-mediated periosteal osteogenesis.Thus,we have introduced a promising therapeutic approach for drug-induced in situ alveolar bone augmentation,which may prevent or repair the detrimental periodontal dehiscence,holding significant potential in dentistry.
基金supported by grants from National Natural Science Foundation of China(82272444,81972031,81972033)China Postdoctoral Science Foundation(2022M722382)Tianjin Key Medical Discipline(Specialty)Construction Project(TJYXZDXK-032A)。
文摘Neural EGFL-like 2(NELL2)is a secreted protein known for its regulatory functions in the nervous and reproductive systems,yet its role in bone biology remains unexplored.In this study,we observed that NELL2 was diminished in the bone of aged and ovariectomized(OVX)mice,as well as in the serum of osteopenia and osteoporosis patients.In vitro loss-of-function and gain-offunction studies revealed that NELL2 facilitated osteoblast differentiation and impeded adipocyte differentiation from stromal progenitor cells.In vivo studies further demonstrated that the deletion of NELL2 in preosteoblasts resulted in decreased cancellous bone mass in mice.Mechanistically,NELL2 interacted with the FNI-type domain located at the C-terminus of Fibronectin 1(Fn1).Moreover,we found that NELL2 activated the focal adhesion kinase(FAK)/AKT signaling pathway through Fn1/integrinβ1(ITGB1),leading to the promotion of osteogenesis and the inhibition of adipogenesis.Notably,administration of NELL2-AAV was found to ameliorate bone loss in OVX mice.These findings underscore the significant role of NELL2 in osteoblast differentiation and bone homeostasis,suggesting its potential as a therapeutic target for managing osteoporosis.
文摘The published article titled“Procaine inhibits the proliferation and migration of colon cancer cells through inactivation of the ERK/MAPK/FAK pathways by regulation of RhoA”has been retracted from Oncology Research,Vol.26,No.2,2018,pp.209–217.
文摘目的:研究粘着斑激酶(focal adhesion kinase,FAK)、磷酸化粘着斑激酶(phospho-FAK,Y397)、与张力蛋白同源的第10号染色体丢失的磷酸酶基因(phosphatase and tensinhomolog deleted on chromosome,PTEN)在胃腺癌及癌旁组织中的表达及其临床意义。方法:采用免疫组织化学S-P法检测FAK、p-FAK(Y397)和PTEN在100例胃腺癌和30例癌旁组织中的表达。结果:胃腺癌与癌旁组织FAK阳性表达率分别为71%(71/100)、43%(13/30)(P<0.05);P-FAK(Y397)阳性表达率分别为62%(62/100)、20%(6/30)(P<0.05);PTEN阳性表达率分别为53%(53/100)、97%(29/30)(P<0.05);癌组织中FAK、p-FAK(Y397)、PTEN的表达与胃腺癌分化程度、浸润深度、淋巴结转移及TNM分期有关(P<0.05),与年龄、性别无关(P>0.05);PTEN与FAK、P-FAK(Y397)在胃腺癌中的表达呈负相关(r=-0.514,-0.572;P<0.05),FAK与p-FAK(Y397)呈正相关(r=0.539;P<0.05)。结论:胃腺癌中存在FAK和p-FAK(Y397)表达上调,PTEN表达下调,三者的表达水平可能与胃腺癌的发生、发展有关。
文摘目的:研究青娥方对去卵巢大鼠骨组织FAK表达及骨代谢生化指标的影响。方法:96只3月龄雌性SD大鼠随机分为假手术组、单纯去卵巢组、骨疏康组、青娥方组。前两组灌服0.9%氯化钠溶液,后两组分别灌服骨疏康及青娥方。分别于用药4、8、12周检测大鼠腰椎FAK m RNA及蛋白含量、胫骨骨密度(BMD)、血清骨碱性磷酸酶(BALP)、酸性磷酸酶(TRAP-5b)、尿脱氧吡啶吩(DPD)、尿肌酐(Cr)等的变化。结果:用药4、8、12周,与假手术组比较,单纯去卵巢组骨FAK m RNA及蛋白表达明显升高(P<0.01),随着时间推移逐渐越低。BMD及血TRAP-5b持续下降,血BALP呈先升高后下降态势,尿DPD/Cr持续升高。青娥方干预4、8、12周,骨FAK m RNA及蛋白表达持续下降,明显低于单纯去卵巢组(P<0.05,P<0.01)。用药8、12周,与单纯去卵巢组比较,青娥方组血BALP、血TRAP-5b水平较之前明显改善(P<0.05,P<0.01);用药12周后,BMD及尿DPD/Cr明显高于单纯去卵巢组(P<0.01),与假手术组相比无明显差异。结论:青娥方能抑制骨组织FAK的表达,提高BMD及血BALP水平,降低血TRAP-5b及尿DPD/Cr含量,降低去卵巢大鼠的骨吸收速度。
文摘目的观察化痰消瘀方对胃癌前病变大鼠PTEN、FAK及paxillin表达的影响,从分子生物学水平探讨其逆转胃癌前病变的作用机制。方法选择90只4~5周龄SD雄性大鼠,随机取15只作为空白组,其余大鼠均采用N-甲基-N’-硝基N-亚硝基胍综合饥饱失常、浓盐水灌胃的方法制备胃癌前病变大鼠模型。将造模成功大鼠随机分为模型组,中药高、中、低剂量组及维酶素组,每组13只。空白组正常饮食,余均造模成功后,模型组给予生理盐水灌胃,中药高、中、低剂量组分别给予3 m L/kg、2 m L/kg、1 m L/kg化痰消瘀方灌胃,维酶素组给予10 m L/kg维酶素灌胃,均灌胃8周。采用HE染色法观察大鼠胃黏膜病理改变情况,应用免疫组化法检测胃黏膜组织中PTEN、FAK及paxillin的表达情况。结果 HE染色显示空白组大鼠胃黏膜无癌前病变改变,模型组均出现不同程度的胃癌前病变改变,中药高、中剂量组和维酶素组胃黏膜癌前病变情况均较模型组明显改善（P均〈0.05）,且中药高剂量组改善程度高于其他各给药组（P均〈0.05）。免疫组化结果显示PTEN在空白组强阳性表达;模型组鲜有表达;中药高、中、低剂量组表达量逐渐降低,但高于模型组（P均〈0.05）;中药高剂量组PTEN表达量高于其他各给药组（P均〈0.05）。FAK、paxillin在空白组极少表达,模型组表达量较空白组显著增加（P均〈0.05）;中药高、中、低剂量组二者表达量均明显低于模型组（P均〈0.05）,其中高剂量组表达量明显低于其他各给药组（P均〈0.05）。结论中药化痰消瘀方可显著改善胃癌前病变大鼠胃黏膜组织病理学情况,其作用机制可能是激活抑癌基因PTEN,调节FAK的去磷酸化,通过FAK/Src信号通路下调paxillin来诱导细胞凋亡。
